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Oral pre-exposure prophylaxis (PrEP) is highly effective for HIV prevention, but data are lim-
ited on HIV incidence among PrEP users in generalized epidemic settings, particularly out-
side of selected risk groups. We performed a population-based PrEP study in rural Kenya
and Uganda and sought to evaluate both changes in HIV incidence and clinical and virologic
outcomes following seroconversion on PrEP.
Methods and findings
During population-level HIV testing of individuals�15 years in 16 communities in the Sustain-
able East Africa Research in Community Health (SEARCH) study (NCT01864603), we offered
universal access to PrEP with enhanced counseling for persons at elevated HIV risk (based
on serodifferent partnership, machine learning–based risk score, or self-identified HIV risk).
We offered rapid or same-day PrEP initiation and flexible service delivery with follow-up visits
at facilities or community-based sites at 4, 12, and every 12 weeks up to week 144. Among
participants with incident HIV infection after PrEP initiation, we offered same-day antiretroviral
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therapy (ART) initiation and analyzed HIV RNA, tenofovir hair concentrations, drug resistance,
and viral suppression (<1,000 c/ml based on available assays) after ART start. Using Poisson
regression with cluster-robust standard errors, we compared HIV incidence among PrEP initi-
ators to incidence among propensity score–matched recent historical controls (from the year
before PrEP availability) in 8 of the 16 communities, adjusted for risk group. Among 74,541
individuals who tested negative for HIV, 15,632/74,541 (21%) were assessed to be at elevated
HIV risk; 5,447/15,632 (35%) initiated PrEP (49% female; 29% 15–24 years; 19% in serodif-
ferent partnerships), of whom 79% engaged in�1 follow-up visit and 61% self-reported PrEP
adherence at�1 visit. Over 7,150 person-years of follow-up, HIV incidence was 0.35 per 100
person-years (95% confidence interval [CI] 0.22–0.49) among PrEP initiators. Among
matched controls, HIV incidence was 0.92 per 100 person-years (95% CI 0.49–1.41), corre-
sponding to 74% lower incidence among PrEP initiators compared to matched controls
(adjusted incidence rate ratio [aIRR] 0.26, 95% CI 0.09–0.75; p = 0.013). Among women, HIV
incidence was 76% lower among PrEP initiators versus matched controls (aIRR 0.24, 95% CI
0.07–0.79; p = 0.019); among men, HIV incidence was 40% lower, but not significantly so
(aIRR 0.60, 95% CI 0.12–3.05; p = 0.54). Of 25 participants with incident HIV infection (68%
women), 7/25 (28%) reported taking PrEP�30 days before HIV diagnosis, and 24/25 (96%)
started ART. Of those with repeat HIV RNA after ART start, 18/19 (95%) had <1,000 c/ml.
One participant with viral non-suppression was found to have transmitted viral resistance, as
well as emtricitabine resistance possibly related to PrEP use. Limitations include the lack of
contemporaneous controls to assess HIV incidence without PrEP and that plasma samples
were not archived to assess for baseline acute infection.
Conclusions
Population-level offer of PrEP with rapid start and flexible service delivery was associated with
74% lower HIV incidence among PrEP initiators compared to matched recent controls prior to
PrEP availability. HIV infections were significantly lower among women who started PrEP.
Universal HIV testing with linkage to treatment and prevention, including PrEP, is a promising




Why was this study done?
• Despite major gains in HIV testing and treatment, there were 1.7 million new HIV
infections worldwide in 2019, of which nearly 60% occurred in sub-Saharan Africa.
• Daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtrici-
tabine (TDF/FTC) is highly effective for HIV prevention and could substantially reduce
new HIV infections if offered alongside access to HIV testing and treatment.
• Little is known about the incidence of new HIV infections among PrEP users in settings
with generalized HIV epidemics, particularly when offered broadly across communities
where access to HIV testing and treatment have already been scaled up.
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What did the researchers do and find?
• In 16 communities in rural Kenya and Uganda, we conducted community-wide HIV
testing and offered universal access to PrEP with an inclusive approach to eligibility (for
persons in serodifferent partnerships, those identified by an HIV risk prediction tool, or
those who self-identified as being at risk of HIV). We offered rapid PrEP start and a flex-
ible care delivery model with follow-up visits at health facilities or community-based
sites for HIV testing and PrEP refills.
• Of 74,541 persons who tested negative for HIV, 15,632 (21%) were assessed to be at ele-
vated HIV risk, of whom 5,447 (35%) started PrEP. Overall, 79% of persons who initi-
ated PrEP engaged in the program for follow-up visits.
• Among PrEP initiators in the 16 study communities, there were 25 seroconversions
over 7,150 person-years of follow-up. HIV incidence was 0.35 per 100 person-years
(95% confidence interval [CI] 0.22–0.49).
• In 8 communities, we compared HIV incidence among PrEP initiators to persons
with similar characteristics (matched controls) from the year before PrEP was avail-
able. Compared to matched controls, HIV incidence was 74% lower among PrEP ini-
tiators overall; 76% lower among women who initiated PrEP; and 40% lower among
men who initiated PrEP, although this result among men did not reach statistical
significance.
What do these findings mean?
• Providing universal access to PrEP in the context of community-wide HIV testing in
rural Kenya and Uganda was associated with lower HIV incidence among persons who
initiated PrEP compared to matched recent controls.
• We found lower HIV incidence after PrEP initiation among women, for whom rates of
new HIV infections are higher than in men, including in recent prevention studies with-
out PrEP. These results suggest that PrEP may help to close the gap in new infections
between men and women.
• Universal access to HIV testing, treatment, and prevention, including rapid provision of
PrEP with flexible service delivery, could reduce HIV incidence in generalized epidemic
settings.
Introduction
In 2019, there were 1.7 million new HIV infections globally, far exceeding the UNAIDS 2020
target of 500,000 new infections annually [1]. Oral pre-exposure prophylaxis (PrEP) with teno-
fovir disoproxil fumarate/emtricitabine (TDF/FTC) is highly effective for HIV prevention
[2,3] and could accelerate reductions in HIV incidence in combination with other approaches
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such as treatment as prevention [4]. In high-income settings where both antiretroviral therapy
(ART) and PrEP have been scaled up, declines in incidence have been observed among men
who have sex with men (MSM) [5,6]. In sub-Saharan Africa, which accounted for 59% of new
infections globally in 2019 [1], there have been remarkable gains in ART coverage, but PrEP
rollout is just beginning to expand in many settings. As a result, data on HIV incidence among
PrEP users in Africa remain limited outside of placebo-controlled trials and open-label studies
of specific risk groups, such as serodifferent couples [7], young women [8], MSM [9], and
female sex workers [10].
As PrEP is scaled up in generalized epidemic settings, optimal strategies for delivery (includ-
ing care provision, refills, and laboratory monitoring) are needed to realize its potential to reduce
new HIV infections. Community-based HIV testing with supported linkage to treatment or pre-
vention, including PrEP, provides an opportunity to engage individuals (such as adolescent girls,
young adults, and men) who may not otherwise access health services. Moreover, lower-barrier
models for PrEP service delivery, including options for out-of-facility community-based visits,
may further help to enhance retention of individuals in HIV prevention services.
We offered universal access to PrEP with an inclusive approach to eligibility during popula-
tion-level HIV testing in 16 communities in rural Kenya and Uganda. We provided rapid
PrEP start on-site at health fairs and at clinics and a flexible delivery model with follow-up vis-
its at either clinics or community-based sites for both HIV testing and PrEP refills. We sought
to evaluate HIV incidence among PrEP initiators and characterize incident HIV infections on
PrEP, including clinical and virologic outcomes.
Methods
Ethics statement
This study was approved by the institutional review boards of Makerere University (Kampala,
Uganda), Kenya Medical Research Institute (Nairobi, Kenya), and University of California,
San Francisco (UCSF; San Francisco, California, United States of America). All participants
provided verbal consent; PrEP participants provided written informed consent in their pre-
ferred language. This study is reported as per the STROBE Statement (S1 STROBE Checklist).
Study design and procedures
The Sustainable East Africa Research in Community Health (SEARCH) study (NCT01864603)
is a cluster-randomized controlled trial in 32 communities in rural Kenya and Uganda that
began in 2013 to test the hypothesis that HIV “test and treat” with universal ART using a
multi-disease, patient-centered care model would reduce new HIV infections and improve
community health compared to a country guideline approach [11]. In 2016 to 2017, the study
implemented a population-level PrEP intervention in 16 communities before national PrEP
rollout in Kenya and Uganda. As previously described [12,13], from 2016 to 2017, we con-
ducted community sensitization and education on PrEP and offered universal access to PrEP
during population-level HIV and multi-disease testing, using a hybrid mobile testing approach
[14]. Our approach involved holding health fairs at multiple locations across each community
over 2 weeks, followed by home-based testing for non-attendees. We offered enhanced indi-
vidual counseling on PrEP to persons with elevated risk of HIV acquisition based on at least
one of the following categories: persons in serodifferent partnerships; those classified as being
at risk based on an empirical HIV risk prediction algorithm developed using machine learning
[15]; and individuals who self-identified as being at risk [12]. We offered rapid or same-day
PrEP initiation (with medication provided by the study) at local government clinics (with one-
time, study-provided transport). In 14 of 16 communities, on-site PrEP start was also offered
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at SEARCH community-wide health fairs. From 2017 to 2018, we also offered on-site PrEP ini-
tiation during HIV testing events for key populations, tailored to the epidemiology of each
community and including groups such as serodifferent partners, young women, and persons
working in the fishing or transportation industries, or in bars [16]. In addition, PrEP initiation
was offered through the SEARCH study on an ongoing basis at clinics in study communities.
PrEP eligibility criteria included negative HIV testing within the preceding 4 weeks, no
known hepatitis B infection, and no acute HIV symptoms. Baseline creatinine testing was per-
formed, but PrEP was provided at enrollment before the receipt of creatinine results. After
providing written informed consent, participants were given TDF (300 mg) co-formulated
with FTC (200 mg). In a small number of cases, TDF co-formulated with lamivudine (3TC;
150 mg) was provided as an alternative to TDF/FTC due to limitations in drug supply, in
accordance with guidelines [17,18].
Follow-up visits were scheduled at week 4, week 12, and every 12 weeks thereafter for up to
144 weeks prior to referral to local clinics for ongoing care. We provided a flexible delivery
system with options for follow-up visits at clinics or community locations of the participants’
choice (e.g., homes, near schools, trading centers, or beaches). Follow-up visit procedures
included evaluation of self-assessed HIV risk, self-reported PrEP adherence using 3-day recall
[19] (a feasible-to-collect measure), rapid HIV antibody testing using country-standard serial
testing algorithms, and PrEP refills. Participants who stopped PrEP were offered HIV testing
and the opportunity to restart PrEP at each visit.
Procedures for participants with incident HIV infection after PrEP
initiation
Same-day ART start with standard regimens (TDF and 3TC with efavirenz [EFV] or, later,
dolutegravir) recommended in Ugandan [20] and Kenyan [17,21] treatment guidelines was
offered at the seroconversion visit (i.e., on the day of positive testing with 2 rapid antibody
tests). Confirmatory testing with HIV RNA was performed, followed by testing with Geenius
HIV 1/2 Supplemental Assay (Bio-Rad, Hercules, California, USA) or western blot if HIV
RNA not detected. Resistance to antiretroviral drugs was assessed by standard consensus
sequencing from a stored plasma sample collected at the seroconversion visit or the visit closest
to the seroconversion visit. Among participants who self-reported taking PrEP�30 days prior
to seroconversion, we analyzed tenofovir concentrations in small hair samples (50 to 100
strands) to estimate the number of PrEP doses taken per week [22,23]. One centimeter of hair
closest to the scalp (reflecting the most recent 4 weeks of drug exposure) was analyzed via liq-
uid chromatography-tandem mass spectrometry (LC-MS/MS) using validated methods in the
UCSF Hair Analytical Laboratory [22]. Among participants with incident HIV infection, we
assessed viral suppression rates�12 months after ART start. A threshold for viral suppression
of HIV RNA <1,000 copies/ml was selected based on the highest limit of detection of assays
used during routine follow-up (ranging from <20 to<1,000 copies/ml).
Statistical analysis
We analyzed the following steps of the PrEP cascade, based on methods previously described
[12], with data updated in this analysis through database closure (June 17, 2020). Among indi-
viduals assessed to be at elevated HIV risk, we calculated the proportion with PrEP uptake,
defined as initiation based on receipt of pills. Among individuals who initiated PrEP, we mea-
sured program engagement, defined as attendance at follow-up visits. At each follow-up visit,
we assessed the proportion of individuals who (1) received PrEP medication refills; and (2)
self-reported adherence to PrEP (at least 1 dose of the past 3 [an indication of any recent PrEP
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use], making the assumption that the participants not seen were nonadherent), both among all
individuals who initiated PrEP and among individuals who reported current HIV risk.
We analyzed the HIV incidence rate among PrEP initiators who had repeat HIV testing
after PrEP initiation. Incident HIV infections were those confirmed by HIV RNA, western
blot, or Geenius testing. The date of HIV infection was imputed as the midpoint between last
negative and first positive test. Follow-up time was censored at the date of death, last visit
before database closure, or the imputed infection date. Incidence rates were calculated overall
and by sex with 95% confidence intervals (CIs) defined by 2.5th and 97.5th quantiles over
5,000 bootstrap samples.
We conducted an analysis to compare observed HIV incidence among PrEP initiators to
expected HIV incidence without PrEP. Because a contemporaneous control group without
access to PrEP and with repeat HIV testing to detect seroconversions was not available, we
compared HIV incidence among PrEP initiators to HIV incidence among propensity score–
matched recent controls over the year before PrEP was available through this study. This anal-
ysis was thus restricted to the 8 study communities in which population-level HIV testing was
performed (as described above [14]) 1 year before PrEP was available and was repeated 1 year
later at the start of the PrEP intervention. Individuals in these communities who had a negative
HIV test in 2015 to 2016 and had a repeat HIV test 1 year later (2016 to 2017) were eligible to
contribute to the analysis of matched controls. The dates of population-level HIV testing in
the 8 communities are provided in S1 Table. (In the 8 communities not included in this analy-
sis, population-level HIV testing was not performed the year prior to PrEP availability and,
thus, HIV incidence data were not available). Because PrEP is intended for use among persons
at elevated HIV risk, we selected recent historical controls based on 1-to-1 matching on an
estimated propensity score, with matching performed within each community. Specifically,
the propensity score was defined as the conditional probability of PrEP initiation given the fol-
lowing HIV risk predictors [24]: demographic factors, including age, sex, occupation, educa-
tion, mobility, alcohol use, and serodifferent partnership (full list in S1 Statistical Analysis
Plan). We estimated the propensity score with the machine learning algorithm Super Learner
[25], using 5-fold interval cross validation. We then selected among the recent controls based
on matching (via the Matching package [24] in R) on the estimated propensity score. Finally,
we calculated incidence rate ratios using Poisson regression with robust standard errors,
accounting for clustering by community. Regression models adjusted for risk group (serodif-
ferent partners, women 15 to 24 years, widow[er]s, fishing/bar/transport workers, and alcohol
users) to account for any residual differences between the risk profiles of PrEP initiators and
the matched controls. To examine differences by sex, these analyses were repeated stratifying
on sex. Additional details are available in S1 Statistical Analysis Plan. Analyses were conducted
using R version 3.6.1.
Results
Study participants and PrEP uptake
A total of 76,132 individuals�15 years old not previously diagnosed with HIV received HIV
testing in the 16 study communities (Fig 1) from June 2016 to April 2019. Overall, 74,541
tested negative for HIV, of whom 15,632 (21%) were assessed to be at elevated HIV risk, and
5,447 (35%) initiated PrEP (S2 Table). Among the 5,447 PrEP initiators, 49% were women,
29% were age 15 to 24 years, 16% were age�45 years, and 19% were in serodifferent partner-
ships (Table 1; S3 Table).
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PrEP program engagement, refills, and self-reported adherence
Among 5,398 PrEP initiators eligible for a follow-up visit, 4,271 (79%) engaged in the PrEP
program and attended�1 follow-up visit, 3,578 (66%) received�1 refill, and 3,282 (61%) self-
reported adherence to PrEP at�1 visit. At week 4, 3,512/5,398 (65%) individuals who initiated
PrEP were engaged in the PrEP program, 2,805 (52%) received PrEP refills, and 2,271 (42%)
self-reported adherence to PrEP (at least 1 dose of the last 3) (S1 Fig). At week 60, 2,758 (54%)
of 5,094 eligible participants were engaged in the program, 1,677 (33%) received a refill, and
1,367 (27%) self-reported adherence. Among participants who reported current HIV risk at
follow-up visits, refills and self-reported adherence were higher. At week 60, of the 1,711 par-
ticipants engaged and reporting current HIV risk, 1,601 (94%) received refills and 1,277 (75%)
self-reported adherence. Overall, 83% of PrEP initiators stopped PrEP at least once and 45% of
those later restarted PrEP. Among the 5,447 participants who started PrEP, 145 (2.7%)
received at least 1 fill of TDF/3TC (rather than TDF/FTC).
In analyses stratified by sex, women were more likely than men to engage in PrEP visits,
receive refills, and report adherence at each study visit through week 60 (S2 Fig). Moreover,
throughout the study, women were more likely than men to ever engage in visits, receive refills,
or report adherence (82%, 69%, and 65%, respectively, among women compared to 75%, 62%,
and 56% among men). In analyses by age–sex strata, at week 24, youth ages 15 to 24 years were
less likely to engage in all steps of the PrEP cascade and to report current HIV risk compared
to older groups (S3 Fig).
HIV incidence among PrEP initiators
Among 5,447 PrEP initiators, 4,260 (78%) had at least 1 subsequent HIV test after PrEP initia-
tion (S4 Table). There were 25 incident HIV infections over 7,150 person-years of follow-up.
The HIV incidence rate was 0.35 per 100 person-years (95% CI 0.22 to 0.49) overall, 0.46 per
100 person-years (95% CI 0.24 to 0.68) among women, and 0.23 per 100 person-years (95% CI
0.09 to 0.41) among men (Fig 2).
Fig 1. PrEP uptake following population-level HIV testing in 16 communities in rural Kenya and Uganda.
Individuals assessed to be at elevated risk of HIV acquisition (based on serodifferent partnership, HIV risk score, or
otherwise self-identified HIV risk) were offered enhanced individual counseling on PrEP. Individuals neither in
serodifferent partnerships nor identified by the risk score could self-identify as at risk of HIV acquisition. PrEP, pre-
exposure prophylaxis.
https://doi.org/10.1371/journal.pmed.1003492.g001
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Table 1. Baseline characteristics of individuals who initiated PrEP in 16 communities in rural Kenya and Uganda.
PrEP initiators
(N = 5,447)
Sex Female 2,674 (49.1%)
Male 2,773 (50.9%)





Educational attainmenta Less than primary level 292 (5.4%)
Primary school level 3,279 (60.2%)
Any secondary school level or higher 1,213 (22.3%)
Occupationb Farmer 2,330 (42.8%)
Student 247 (4.5%)
Fishing, bar, or transportation 1,102 (20.2%)
Other informal sector 981 (18.0%)
Other formal sector 203 (3.7%)
Unemployed or disabled 218 (4.0%)
Other or unknown 19 (0.3%)
Marital statusc Not married 1,053 (19.3%)
Married (monogamous) 2,618 (48.1%)
Married (polygamous) 960 (17.6%)
Divorced, separated, or widowed 469 (8.6%)
Serodifferent partner Yes 1,026 (18.8%)
No or unknown 4,421 (81.2%)
Circumcisiond Medical 742 (26.8%)
Traditional 452 (16.3%)
Uncircumcised 1,241 (44.8%)
Alcohol usee None 3,896 (71.5%)
1–7 days per month 357 (6.6%)
>7 days per month 536 (9.8%)
Mobilityf Yes 315 (5.8%)
No 4,751 (87.2%)
Region Western Kenya 2,413 (44.3%)
Eastern Uganda 1,471 (27.0%)
Western Uganda 1,563 (28.7%)
aMissing data for 663 (12.2%) individuals.
bOther formal sector occupations: teaching, government, military, healthcare, and factory work. Other informal
sector occupations: shopkeeper, market vendor, hotel worker, homemaker, household worker, miner, and
construction. Missing data for 347 (6.4%) individuals.
cMissing data for 347 (6.3%) individuals.
dAssessed among 2,773 men. Missing data for 338 (12.2%) individuals.
eMissing data for 658 (12.1%) individuals.
fMobility defined as migration out of the community for at least 1 month or moved residence within the past 12
months. Missing data for 381 (7.0%) individuals.
PrEP, pre-exposure prophylaxis.
https://doi.org/10.1371/journal.pmed.1003492.t001
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HIV incidence among PrEP initiators compared to HIV incidence among
recent matched controls prior to PrEP availability
In 8 of the 16 study communities, we compared observed HIV incidence among PrEP initia-
tors to HIV incidence without PrEP, based on propensity score–matched recent controls from
the year before PrEP was available. Median follow-up time among matched recent controls
was 0.90 years (interquartile range [IQR] 0.83 to 0.97) compared to 1.61 years (IQR 1.02 to
2.45) among PrEP initiators. Among matched recent controls (in the absence of PrEP), there
were 17 incident HIV infections over 1,848 person-years of follow-up; the HIV incidence rate
was 0.92 per 100 person-years (95% CI 0.49 to 1.41; S5 Table). Among PrEP initiators in the
same 8 communities, there were 11 incident HIV infections over 3,393 person-year of follow-
up; the HIV incidence rate was 0.32 per 100 person-years (95% CI 0.15 to 0.53), corresponding
to 74% lower HIV incidence among PrEP initiators compared to matched recent controls
(adjusted incidence rate ratio [aIRR] 0.26, 95% CI 0.09 to 0.75; p = 0.013; Fig 3). Among
women, HIV incidence among matched controls was 1.52 per 100 person-years (95% CI 0.70
to 2.36) compared to 0.40 per 100 person-years (95% CI 0.12 to 0.73) observed among PrEP
initiators, corresponding to 76% lower HIV incidence among PrEP initiators compared to
matched recent controls (aIRR 0.24, 95% CI 0.07 to 0.79; p = 0.019). Among men, HIV inci-
dence among matched controls was 0.40 per 100 person-years (95% CI 0.10 to 0.90) compared
to 0.24 per 100 person-years (95% CI 0.06 to 0.49) observed among PrEP initiators, corre-
sponding to 40% lower HIV incidence that was not statistically significant among PrEP initia-
tors compared to matched recent controls (aIRR 0.60, 95% CI 0.12 to 3.05; p = 0.54).
Excluding 3 PrEP participants (all women) who seroconverted at the week 4 visit (and were
thus possibly acutely infected at enrollment), HIV incidence was 0.31 per 100 person-years
(95% CI 0.18 to 0.45) overall and 0.37 per 100 person-years (95% CI 0.19 to 0.59) among
women. Observed incidence was 78% lower among PrEP initiators compared to matched
recent controls (overall aIRR 0.22, 95% CI 0.07 to 0.67, p = 0.0078; among women: aIRR 0.17,
Fig 2. Observed HIV incidence rate among PrEP initiators, overall and stratified by sex. Observed HIV incidence rate per 100
person-years among PrEP initiators in all 16 study communities. CI, confidence interval; PrEP, pre-exposure prophylaxis; PY, person-
years.
https://doi.org/10.1371/journal.pmed.1003492.g002
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95% CI 0.05 to 0.59, p = 0.0054). Stored plasma was not collected at enrollment to determine
whether these individuals were acutely infected at the time of PrEP initiation.
Demographics and adherence levels among participants with incident HIV
infection
Among the 25 individuals with incident HIV infection following PrEP initiation, 17/25 (68%)
were women (Table 2). Among the 17 women with incident HIV infection, 8 (47%) had a sero-
different partner at PrEP enrollment compared to 1 (13%) of 8 men. At the seroconversion
visit, the median age among women was 27 years (range 20 to 62) and among men was 35
years (range 22 to 49). Regarding adherence, 18/25 (72%) participants reported not taking
PrEP for>30 days before the seroconversion visit. One participant with incident HIV infec-
tion received TDF/3TC as PrEP once (of 10 fills); the remaining participants with incident
HIV infection received only TDF/FTC.
Of the 7/25 (28%) participants who reported taking at least 1 dose of PrEP in the last 30
days, 4 reported intermittent PrEP adherence in the last 3 months (2 had tenofovir levels in
hair consistent with taking an average of 4 to 6 PrEP doses/week in the last 4 weeks; 1 had lev-
els consistent with 7 doses/week; and 1 had no hair sample available). One participant had
2-class antiretroviral (ARV) drug resistance (described below) and high adherence (tenofovir
levels in hair consistent with 7 doses/week). Three participants seroconverted at the week 4
visit and were possibly acutely infected at enrollment; one reported nonadherence to PrEP,
while 2 reported adherence (confirmed by hair levels consistent with 7 doses/week).
Clinical and virologic outcomes among participants with incident HIV
infection
Median plasma HIV RNA concentration at the seroconversion visit was 5,871 c/ml (range
<40 to 177,293 c/ml) among the 7 participants reporting adherence to PrEP in the last 30
days. Among the 18 participants who reported no recent PrEP use, median HIV RNA was
Fig 3. Observed HIV incidence rate among PrEP initiators compared to HIV incidence among recent matched
controls prior to PrEP availability, overall and stratified by sex. HIV incidence rate per 100 person-years in 8 study
communities with propensity score–matched recent historical controls. CI, confidence interval; PrEP, pre-exposure
prophylaxis.
https://doi.org/10.1371/journal.pmed.1003492.g003
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24,217 c/ml (range 76 to 1.47 million c/ml). Two participants who seroconverted at the week 4
visit and had evidence of high adherence based on tenofovir concentrations in hair had HIV
RNA <40 c/ml (with confirmation of seroconversion by western blot or Geenius).
Among the 25 participants with incident HIV infection, 24/25 (96%) started ART, of whom
16/24 (67%) started same day and 21/24 (88%) within 7 days of the seroconversion visit. All 24







Age, years 15–24 7 (28.0%) 5 (29.4%) 2 (25.0%)
25–34 11 (44.0%) 8 (47.1%) 3 (37.5%)
35–44 3 (12.0%) 1 (5.9%) 2 (25.0%)
45–54 2 (8.0%) 1 (5.9%) 1 (12.5%)
�55 2 (8.0%) 2 (11.8%) 0 (0.0%)
Educational attainmenta Less than primary level 1 (4.0%) 1 (5.9%) 0 (0.0%)
Primary school level 17 (68.0%) 12 (70.6%) 5 (62.5%)
Any secondary school level or higher 3 (12.0%) 1 (17.6%) 2 (25.0%)
Occupationb Farmer 8 (32.0%) 7 (41.2%) 1 (12.5%)
Student 0 (0.0%) 0 (0.0%) 0 (0.0%)
Fishing, bar, or transportation 6 (24.0%) 1 (5.9%) 5 (62.5%)
Other informal sector 6 (24.0%) 5 (29.4%) 1 (12.5%)
Other formal sector 0 (0.0%) 0 (0.0%) 0 (0.0%)
Unemployed or disabled 1 (4.0%) 1 (5.9%) 0 (0.0%)
Other or unknown 0 (0.0%) 0 (0.0%) 0 (0.0%)
Marital statusc Not married 2 (8.0%) 1 (5.9%) 1 (12.5%)
Married (monogamous) 8 (32.0%) 4 (23.5%) 4 (50.0%)
Married (polygamous) 7 (28.0%) 5 (29.4%) 2 (25.0%)
Divorced, separated, or widowed 4 (16.0%) 4 (23.5%) 0 (0.0%)
Serodifferent partner Yes 9 (36.0%) 8 (47.1%) 1 (12.5%)
No or unknown 16 (64.0%) 9 (52.9%) 7 (87.5%)
Circumcisiond Medical NA NA 2 (25.0%)
Traditional NA NA 1 (12.5%)
Uncircumcised NA NA 4 (50.0%)
Alcohol usee None 18 (72.0%) 14 (82.4%) 4 (50.0%)
1–7 days per month 0 (0.0%) 0 (0.0%) 0 (0.0%)
>7 days per month 3 (12.0%) 0 (0.0%) 3 (37.5%)
Mobilityf Yes 0 (0.0%) 0 (0.0%) 0 (0.0%)
No 21 (84.0%) 14 (82.4%) 4 (50.0%)
Region Western Kenya 10 (40.0%) 6 (35.3%) 4 (50.0%)
Eastern Uganda 8 (32.0%) 5 (29.4%) 3 (37.5%)
Western Uganda 7 (28.0%) 6 (35.3%) 1 (12.5%)
aMissing data for 1 (12.5%) male and 3 (17.6%) female individuals.
bOther formal sector occupations: teaching, government, military, healthcare, and factory work. Other informal sector occupations: shopkeeper, market vendor, hotel
worker, homemaker, household worker, miner, and construction. Missing data for 1 (12.5%) male and 3 (17.6%) female individuals.
cMissing data for 1 (12.5%) male and 3 (17.6%) female individuals.
dAmong men. Missing data for 1 (12.5%) individual.
eMissing data for 1 (12.5%) male and 3 (17.6%) female individuals.
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participants started standard first-line ART regimens recommended in national guidelines (22
started EFV-based ART; 2 started dolutegravir-based regimens). Of the 22 participants who
started ART and were due for repeat HIV RNA per national guidelines, 19 had subsequent
HIV RNA measurement and 3 could not be located for repeat testing. One participant had
HIV RNA 79,695 c/ml and was found to have drug resistance on stored plasma from the
seroconversion visit, described below. Among the 18 others, the HIV RNA concentrations
(grouped according to the assay’s limit of detection) were as follows: 3 had HIV RNA <20 c/
ml; 2 had <25 c/ml; 4 had <40 c/ml; 1 had 48 c/ml; 1 had <75 c/ml; 1 had 96 c/ml; and 6 had
<1,000 c/ml. Overall, 18/19 (95%) had HIV RNA <1,000 c/ml.
Drug resistance among participants with incident HIV infection
Ten participants who seroconverted had HIV genotyping results from plasma collected at the
seroconversion visit. Fifteen participants did not have genotyping results available due to assay
failure (n = 7), plasma HIV RNA <500 c/ml (n = 5), lack of stored plasma sample from the
seroconversion visit (n = 2), or declining resistance testing (n = 1). Two of the 10 participants
who underwent genotyping had evidence of drug resistance, while 8 had no viral resistance
mutations detected. One participant had mutations in reverse transcriptase (K103N, E138A)
likely due to transmitted drug resistance to non-nucleoside reverse transcriptase inhibitors
(NNRTI) not related to PrEP use.
The other participant with drug resistance had 2-class ARV resistance, including transmit-
ted NNRTI mutations (K103N, P225H), likely transmitted nucleoside/nucleotide reverse tran-
scriptase inhibitor (NRTI) mutations (D67N, K70R, K219Q; thymidine analogue mutations,
conferring low-level TDF resistance), and an M184V mutation (conferring high-level FTC and
3TC resistance) that was either transmitted or acquired on PrEP. This participant had periods
of high levels of PrEP adherence based on tenofovir levels consistent with daily dosing sepa-
rated by missed visits (S4 Fig). HIV RNA at the seroconversion visit was 177,293 c/ml. This
participant experienced viral non-suppression (HIV RNA 79,695 c/ml) on TDF/3TC/EFV
prior to receipt of the results of drug resistance testing from the seroconversion visit and was
subsequently switched to second-line ART.
Discussion
During population-level HIV testing of over 75,000 individuals in 3 regions across rural Kenya
and Uganda, we offered universal PrEP access with flexible service delivery to persons at ele-
vated risk of HIV acquisition. Of more than 15,000 individuals assessed to be at elevated HIV
risk, over 5,400 participants started PrEP, and of these, 79% engaged in the PrEP program for
follow-up visits. Over 7,150 person-years of follow-up, HIV incidence was 0.35 per 100 per-
son-years among PrEP initiators. In 8 communities with propensity score–matched controls,
HIV incidence was 74% lower among PrEP initiators compared to recent controls in the year
before PrEP availability. These results provide supporting evidence that, in generalized epi-
demic settings, universal access to PrEP with flexible service delivery could reduce HIV inci-
dence on top of universal test and treat (UTT) strategies [26]. Moreover, despite concerns
from early placebo-controlled PrEP trials among women in which adherence to study product
was too low for effectiveness [27,28], our study found lower HIV incidence among women
who started open-label PrEP in real-world settings as compared to recent controls.
Our study offered PrEP in the context of universal HIV testing with supported linkage to
either treatment or prevention based on HIV status [29]. We used an inclusive approach to
define PrEP eligibility for HIV-uninfected individuals (based on serodifferent partnership, a
risk score, or self-identified HIV risk). We offered same-day PrEP start (on-site at health fairs),
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an approach that was generally safe, as our group and others have reported [12,30,31]. We also
offered a flexible PrEP delivery model with options for clinic- or community-based follow-up
visits for HIV testing and PrEP refills. We posited that this lower-barrier delivery model would
allow individuals to engage in taking PrEP who might not otherwise access health systems or
facility-based HIV prevention services. Within this flexible model, we found that self-reported
adherence was much higher among individuals reporting current HIV risk at follow-up visits
compared to PrEP participants overall. As previously reported, among participants who self-
reported PrEP adherence and current HIV risk, 66% had tenofovir concentrations in hair
reflecting�4 PrEP doses per week and 44% had levels reflecting 7 doses/week [12]. Moreover,
although many participants stopped PrEP at some point, ongoing program engagement pro-
vided opportunities for repeat HIV testing and restarting PrEP at each visit. Indeed, half of
those who stopped PrEP later restarted taking it, suggesting that some participants may have
been attempting to match PrEP use to periods of risk [32]. As PrEP programs extend eligibility
criteria beyond specific risk groups to persons at substantial risk in the general population [21]
and expand services outside of health facilities [33] (e.g., at drop-in centers [34]), our model
and other low-barrier approaches to PrEP delivery could be adapted and scaled up.
We observed a lower HIV incidence among PrEP initiators as compared with historical
controls prior to PrEP availability in the study communities. To our knowledge, our study is
the first in sub-Saharan Africa to assess HIV incidence after population-level offer of PrEP,
including to individuals outside of specific risk groups. Our results add to evidence from stud-
ies in serodifferent couples and younger women that access to PrEP was associated with lower
than expected HIV incidence. In a demonstration study that offered both PrEP and ART to
serodifferent couples in Kenya and Uganda from 2012 to 2015, HIV incidence was 0.2%, rep-
resenting a 96% reduction compared to matched historical controls without PrEP [7]. The his-
torical comparator group in the study dated up to 7 years prior and lacked access to ART (per
guidelines at the time); thus, the reduction in incidence was due to both ART and PrEP. In
another PrEP study that enrolled young women in urban southern Africa [8], HIV incidence
was 1.0% compared to an expected incidence of 3.7% based on mathematical modeling [35].
Most recently, in a contraceptive trial among women that added PrEP to the current standard
of HIV prevention (including counseling, condoms, and management of sexually transmitted
infections) in South Africa, HIV incidence was approximately 50% lower overall (not only
among PrEP initiators) after PrEP availability compared to before [36]. Our findings extend
the evidence base on the effectiveness of open-label PrEP in sub-Saharan Africa and, to our
knowledge, are among the first to demonstrate that offering PrEP at scale can have a substan-
tial impact on HIV incidence.
Among women who initiated PrEP in our study, we found significantly lower HIV inci-
dence compared to matched recent controls. Women remain a critical population for HIV
prevention and are disproportionately impacted by HIV both in our study communities and
across much of sub-Saharan Africa [1]. Indeed, although half of PrEP initiators in our study
were women, they accounted for two-thirds of new infections. Recent population-based stud-
ies, including SEARCH, have shown greater reductions in incidence among men than women
in the context of scale-up of ART [11,37–39]. Thus, primary prevention approaches, such as
PrEP, may be important for reducing incidence among women. Questions have persisted
about the effectiveness of PrEP in women in part because in 2 placebo-controlled PrEP trials
that enrolled younger women not in stable serodifferent partnerships, adherence was too low
to demonstrate efficacy [27,28]. However, PrEP was effective among women in mutually dis-
closed serodifferent partnerships in a placebo-controlled trial [2] and an open-label demon-
stration project [7] in East Africa, as well as among heterosexual men and women in a
placebo-controlled trial in Botswana [40]. Our results add to the evidence that oral PrEP can
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lower HIV incidence among women in sub-Saharan Africa, including some of the first evi-
dence among women who are not in serodifferent partnerships.
Our study also provides insights into the impact of PrEP on HIV incidence among men.
We found that HIV incidence was 40% lower among men who initiated PrEP compared to his-
torical controls, although this result did not reach statistical significance, possibly due to the
small number of new infections in men. Although men have not been systematically priori-
tized for PrEP in generalized epidemic settings (apart from men in serodifferent couples or
MSM), we found substantial interest in PrEP among men, who comprised half of PrEP initia-
tors. One-third of new HIV infections in sub-Saharan Africa occur among men, and primary
prevention options for this group, including male circumcision and PrEP, are critically needed
for men’s own health [41]. In addition, men are an important link in transmission networks
[42,43], and expanding their access to PrEP could accelerate declines in incidence.
The UTT trials demonstrated reductions in HIV incidence when universal HIV testing was
combined with robust linkage and access to ART care [26,37,38]. These studies further showed
that despite achieving high population-level viral suppression, UTT is not sufficient to reach
HIV elimination targets. Our study provides evidence of the added impact of PrEP in commu-
nities that had already exceeded the UNAIDS 90-90-90 targets for HIV testing, ART coverage,
and viral suppression following UTT. For countries that adopt a UTT approach in areas such
as regional hotspots, leveraging the opportunity for HIV prevention, with inclusive eligibility
and low-barrier delivery, is supported by our results.
Although we observed lower incidence among PrEP initiators compared to recent controls,
PrEP uptake and engagement were lower in youth and mobile individuals, as we have previ-
ously described [12]. Thus, additional innovations are needed to reach these critical groups
and provide tailored service delivery and adherence support for oral PrEP. Moreover, as on-
demand or long-acting prevention modalities (such as the dapivirine vaginal ring [44,45] and
injectable cabotegravir [46]) become available, expanding options for prevention may help to
achieve further reductions in incidence.
Among the 25 participants who seroconverted after initiating PrEP, rapid ART start was
acceptable and feasible and most had excellent virologic outcomes. Earlier PrEP trials in sub-
Saharan Africa offered ART start based on CD4 threshold (per guidelines at the time); thus,
prior studies characterizing seroconversions on PrEP have largely reported on HIV outcomes
in the absence of ART [47–49]. Moreover, few studies have offered rapid ART start (now the
standard of care for new HIV diagnoses [50]) after seroconversion on PrEP, and little is
known about virologic outcomes in this group. In our study, we offered same-day ART start at
the time of positive antibody testing and found that nearly 90% of participants started ART�7
days after the seroconversion visit. Among those with HIV RNA testing after ART initiation,
95% achieved HIV RNA <1,000 c/ml with standard first-line ART regimens. At PrEP follow-
up visits, our study employed quarterly HIV testing using country-standard serial antibody-
based algorithms. This approach may result in delayed detection of acute HIV infection,
potentially increasing the risk of acquiring drug resistance while continuing PrEP and impact-
ing virologic response to ART. To our knowledge, our study is among the first to report on
virologic outcomes after ART start following seroconversion on oral PrEP in any setting glob-
ally [51]. While it is reassuring that most participants who seroconverted in our study achieved
viral suppression on standard first-line ART regimens, robust HIV viral load monitoring
(including rapid and, increasingly, point-of-care technologies [52]) and access to resistance
testing are needed as PrEP use expands.
The only participant who did not achieve viral suppression on repeat testing after ART start
was found to have 2-class drug resistance on testing of stored plasma from the seroconversion
visit. This participant had evidence of transmitted drug resistance based on NNRTI mutations
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and NRTI thymidine analogue mutations (which confer low-level TDF resistance and are
not commonly selected by TDF/FTC alone), as well as high-level FTC and 3TC resistance
(M184V) that was either transmitted or acquired on PrEP. Based on objective adherence data,
this participant had evidence of intermittent high-level adherence to PrEP (tenofovir concen-
trations in hair consistent with daily dosing at multiple visits, including at the seroconversion
visit), separated by missed visits (including the 2 visits prior to seroconversion). There are sev-
eral possible reasons for seroconversion with drug resistance in this case. First, the participant
may have been nonadherent to PrEP during periods of risk, leading to seroconversion, fol-
lowed by adherence to 2-drug PrEP after seroconversion, leading to acquisition of M184V on
top of transmitted NRTI and NNRTI resistance. Second, the participant could have been non-
adherent to PrEP and become infected with a multi-class drug resistant virus (with all muta-
tions transmitted, including the M184V mutation). Third, if periods of adherence matched
periods of risk, seroconversion could have been due to a breakthrough infection in the setting
of high-level FTC resistance and low-level TDF resistance, rendering PrEP ineffective [53]. We
do not have HIV genotyping data from the likely transmission partner to determine if drug
resistance was transmitted or acquired in this case.
HIV acquisition in the setting of high levels of PrEP adherence has been described in several
individuals previously; all were men from North America, Europe, or Asia [54–59]. Notably,
several of these cases had evidence of resistance only to FTC (M184V) without mutations con-
ferring TDF resistance, suggesting that PrEP breakthrough can occur with FTC resistance
alone [54]. For the participant in our study, although breakthrough infection in the setting of
high adherence is one possible explanation for seroconversion (and, to our knowledge, would
be the first such case described in a woman), as noted above, infection also could have been
due to nonadherence during periods of risk. As PrEP is scaled up globally, even with very high
effectiveness, we are likely to observe more seroconversions among PrEP users. Further work
is needed to systematically characterize reasons for seroconversion on PrEP through the use of
pharmacologic adherence metrics (such as measuring PrEP drug levels in hair [60], dried
blood spots [61], or plasma [62]) and drug resistance testing.
This study has several strengths. To our knowledge, our study is among the first and largest
to assess HIV incidence after offering PrEP at a population level. Over three quarters of PrEP
initiators were seen following PrEP initiation, providing among the most complete and longest
follow-up (over 7,000 person-years) to date of any open-label PrEP study in sub-Saharan
Africa. In addition, our estimate of HIV incidence among recent controls was based on robust
population-level HIV testing data in 8 of the 16 study communities in the year prior to PrEP
availability. We offered broad access to PrEP using a community-wide HIV testing model pre-
viously shown to be similar in cost to other mobile testing approaches [63] and feasible for
implementation by community leaders [64].
This study also has limitations. First, we did not compare HIV incidence to a contempora-
neous control where PrEP was unavailable. HIV incidence could have been declining in the
study communities due to secular trends. Over the 3 years prior to PrEP availability in the
study communities, high rates of population-level viral suppression (79%) were achieved, and
population-level HIV incidence declined by 0.12 per 100 person-years [11]. Assuming that
this trend continued during the PrEP study period, we would expect HIV incidence among
matched controls to reduce from 0.92 per 100 person-years (observed 1 year prior to PrEP) to
0.85 per 100 person-years if their follow-up had been contemporaneous. Comparing HIV inci-
dence among PrEP initiators (0.32 per 100 person-years) to this trend-adjusted incidence for
matched controls (0.85 per 100 person-years) suggests that HIV incidence would have been
62% lower among PrEP initiators compared to matched contemporaneous controls. Second,
our analyses of incidence relied on data from individuals with at least 2 HIV tests. However,
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repeat testing coverage was >75% among PrEP initiators and>80% among historical controls
[11], and there were no notable differences between persons with and without a repeat test (S3
Table). Third, despite propensity score matching and adjustment for known risk groups, it
is possible that the risk profiles of PrEP initiators with follow-up testing differed from the
selected controls. If individuals using PrEP were at higher risk than their matched counter-
parts, the estimated change in HIV incidence would be biased toward the null. Finally, because
we used antibody-based screening and did not collect plasma samples at PrEP enrollment,
we are unable to determine whether 3 individuals who tested positive at the week 4 visit were
acutely infected at the time of PrEP initiation. In sensitivity analyses removing these 3 individ-
uals (all women), observed HIV incidence among PrEP initiators and changes in incidence
compared to matched controls were similar to the primary results, overall and among women.
A limitation of this sensitivity analysis is that the control group did not have repeat testing at
week 4, and it is possible that individuals in the control group also had undetected acute infec-
tion at the time of baseline testing.
Community-wide HIV testing and universal access to PrEP were associated with lower
HIV incidence among persons at elevated HIV risk who initiated PrEP in rural Kenya and
Uganda compared to recent controls. Our findings included lower than expected HIV inci-
dence after PrEP initiation among women, for whom declines in new infections have lagged
behind men in recent prevention studies without PrEP. Our results suggest that universal
access to HIV testing, treatment, and prevention, including rapid provision of PrEP with flexi-
ble service delivery, is a promising approach to reduce HIV incidence in generalized epidemic
settings. Moving forward, combination approaches to prevention that include comprehensive
HIV testing with linkage to oral PrEP, male circumcision, and ultimately, on-demand and




S1 Statistical Analysis Plan.
(PDF)
S1 Fig. PrEP program engagement, refills, and self-reported adherence among PrEP initia-
tors, overall and by self-assessed current HIV risk through week 60. Program engagement
defined as attendance at a PrEP follow-up visit during scheduled visit weeks. Excludes partici-
pants withdrawn or deceased before visit. Self-reported adherence: at least 1 PrEP dose taken
in last 3 days. Self-assessed current HIV risk evaluated at each visit among participants
engaged in the PrEP program. PrEP, pre-exposure prophylaxis.
(PDF)
S2 Fig. PrEP program engagement, refills, and self-reported adherence among PrEP initia-
tors through week 60, by sex. Program engagement defined as attendance at a PrEP follow-up
visit during scheduled visit weeks. Excludes participants withdrawn or deceased before visit.
Self-reported adherence: at least 1 PrEP dose taken in last 3 days. PrEP, pre-exposure prophy-
laxis.
(PDF)
S3 Fig. PrEP program engagement, refills, and self-reported adherence at week 24 by age–
sex strata. Program engagement defined as attendance at a PrEP follow-up visit during sched-
uled visit weeks. Excludes participants withdrawn or deceased before visit. Self-reported
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adherence: at least 1 PrEP dose taken in last 3 days. Self-assessed current HIV risk evaluated at
each visit among participants engaged in the PrEP program. PrEP, pre-exposure prophylaxis.
(PDF)
S4 Fig. Timeline of PrEP follow-up, HIV testing, and adherence to PrEP estimated from
tenofovir concentrations in hair for a participant with incident HIV infection with 2-class
antiretroviral drug resistance. Doses of PrEP taken per week in the 4 weeks before study visit,
estimated based on tenofovir concentrations in hair. Timeline indicates study visit week with
days since PrEP initiation in parentheses below visit week for attended visits. Ab, antibody.
ART, antiretroviral therapy; PrEP, pre-exposure prophylaxis.
(PDF)
S1 Table. Community-specific start dates of baseline and repeat population-level HIV test-
ing for matched controls in 8 study communities.
(DOCX)
S2 Table. Baseline characteristics of individuals who tested negative for HIV, those
assessed to be at elevated HIV risk, and PrEP initiators in 16 communities in rural Kenya
and Uganda. PrEP, pre-exposure prophylaxis.
(DOCX)
S3 Table. Baseline characteristics of women and men who initiated PrEP in 16 communi-
ties in rural Kenya and Uganda. PrEP, pre-exposure prophylaxis.
(DOCX)
S4 Table. Baseline characteristics of individuals who initiated PrEP and those with follow-
up HIV testing after PrEP initiation. PrEP, pre-exposure prophylaxis.
(DOCX)
S5 Table. Number of incident HIV infections, person-time at risk (in years), and HIV inci-
dence rate (per 100 person-years) for PrEP initiators in all 16 study communities, PrEP
initiators living in 8 communities where population-based HIV testing was conducted in
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